

December 4, 2025

BSE Limited Code: 532321

P J Towers, Dalal Street, <u>Mumbai-400001</u>

National Stock Exchange of India Limited

Exchange Plaza, C/1, Block G, Bandra-Kurla Complex, Bandra (East), <u>Mumbai-400051</u>

Re.: <u>Press Release</u>

Dear Sir / Madam,

Please find enclosed a copy of press release dated December 4, 2025, titled "Zydus receives EIR for the injectable facility located at Jarod".

The contents of the press release give full details.

Please bring the aforesaid news to the notice of the members of the exchange and the investors' at large.

Yours faithfully, For, **ZYDUS LIFESCIENCES LIMITED**

DHAVAL N. SONI
COMPANY SECRETARY AND COMPLIANCE OFFICER
MEMBERSHIP NO. FCS7063

Encl.: As above



Code: Zyduslife



Zydus receives EIR for the injectable facility located at Jarod

Ahmedabad, India, December 4, 2025

We wish to inform that the company has received the Establishment Inspection Report (EIR) from the USFDA for a GMP follow-up inspection conducted at its injectable facility located at Jarod, Vadodara from August 25 to September 5, 2025 and classifying the facility as Voluntary Action Indicated (VAI). This inspection was conducted following the Warning Letter issued on August 29, 2024 by the USFDA.

This may kindly be considered as a disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Please bring the aforesaid news to the notice of the members of the exchange and the investors at large.



For further information please contact: The Corporate Communications Department

Zydus Lifesciences Limited

Regd. Office: 'Zydus Corporate Park', Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar), Nr. Vaishnodevi Circle, S. G. Highway, Ahmedabad 382 481, Gujarat, India. | Phone: +91-79-71800000, +91-79-48040000 | website: www.zyduslife.com CIN: L24230GJ1995PLC025878